Brief: Xintela Gets Approval For Clinical Study With XSTEM
05/07/2022 14:03
July 5 (Reuters) - Xintela AB XINT.ST :
* XINTELA RECEIVES APPROVAL FOR CLINICAL STUDY WITH XSTEM®
ON
DIFFICULT-TO-HEAL VENOUS LEG ULCERS
* XINTELA HAS TODAY RECEIVED APPROVAL FROM MEDICAL PRODUCTS
AGENCY
FOR A CLINICAL PHASE I/IIA STUDY WITH XSTEM IN PATIENTS WITH
DIFFICULT-TO-HEAL VENOUS LEG ULCERS
* STUDY WILL START AFTER SUMMER AND EARLY RESULTS ARE
EXPECTED BY
END OF 2022
Source text for Eikon: ID:nMFNbsk2Rp
Further company coverage: XINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Xintela AB
See all newsBrief: Xintela To Raise SEK 30 Mln Via Convertible Loan From Flerie Invest
Advisory: Alerts on Xintela's phase I/IIa XSTEM results withdrawn
Brief: Xintela Q1 2026 Loss Before Tax SEK 11.8 Mln
Brief: Xintela Study Finds XSTEM Treatment Safe, Well Tolerated
Brief: Xintela Gets U.S. Patent For Xstem Treatment Of Difficult-To-Heal Wounds, Skin Defects